Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (291-300 of 299) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 299 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2023
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL TrialTom G Jacobs, Vivian Mumbiro, Uneisse Cassia, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Journal of Clinical Pharmacology|September 23, 2021
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic ModelingCarlijn H C Litjens, Laurens F M Verscheijden, Celine Bolwerk, et al.
Journal of the Pediatric Infectious Diseases Society|October 16, 2023
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe PneumoniaChishala Chabala, Tom G Jacobs, Cinta Moraleda, et al.
Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
Eclinicalmedicine|April 22, 2026
Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trialTom G Jacobs, Vivian Mumbiro, John Tembo, et al.
Pageof 30

Showing results (291-300 of 299) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 299 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2023
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL TrialTom G Jacobs, Vivian Mumbiro, Uneisse Cassia, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
Journal of Clinical Pharmacology|September 23, 2021
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic ModelingCarlijn H C Litjens, Laurens F M Verscheijden, Celine Bolwerk, et al.
Journal of the Pediatric Infectious Diseases Society|October 16, 2023
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe PneumoniaChishala Chabala, Tom G Jacobs, Cinta Moraleda, et al.
Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
Eclinicalmedicine|April 22, 2026
Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trialTom G Jacobs, Vivian Mumbiro, John Tembo, et al.
Pageof 30